Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing
New partnership combines Factorial’s in-cell library preparation chemistry with Honeycomb’s HIVE
platform to enable scalable single-cell WGS workflow with processing capacity up to 1 million cells per day.
SAN CARLOS, Calif. and WALTHAM, Mass., Jan. 8, 2026 /PRNewswire/ — Factorial Biotechnologies, a leader in next-generation single-cell sequencing solutions, and Honeycomb Biotechnologies, a pioneer in instrument-free single-cell analysis, today announced a strategic partnership to deliver a flexible and scalable single-cell genomics workflow. The collaboration integrates Factorial’s proprietary in-cell library preparation technology with Honeycomb’s proven HIVE platform, enabling researchers to perform high-throughput single-cell DNA sequencing without specialized instrumentation.
The combined solution offers researchers an accessible pathway to single-cell whole genome sequencing (WGS) with optional hybrid capture target enrichment, now available for beta testing. The companies are also developing a multi-omics protocol capable of simultaneously analyzing DNA, RNA, and protein from individual cells. This instrument-free workflow closely resembles standard bulk NGS protocols, significantly lowering barriers to adoption while maintaining the resolution and data quality required for cutting-edge research.
“What excites me most about this partnership is combining Factorial’s scalable library prep chemistries with an elegant and robust cell partitioning solution,” said John Wells, Founder and CEO of Factorial Biotechnologies. “Honeycomb brings an instrument-free platform that’s already been manufactured and shipped internationally, combined with a decade of knowledge acquired from taking the HIVE from invention through commercialization.”
The partnership addresses a critical need in single-cell genomics: balancing throughput, resolution, and accessibility. Incumbent single-cell DNA sequencing methods sacrifice genomic coverage for throughput or vice versa. By combining Factorial’s extraction-free library preparation chemistry with Honeycomb’s cell barcoding technology, the integrated solution enables researchers to process up to 1 million cells per day using standard laboratory equipment and workflows.
“Honeycomb has always been interested in expanding beyond single-cell RNA sequencing,” said Jim Flanigon, CEO of Honeycomb Biotechnologies. “We are thrilled to be working with Factorial and to extend the capabilities of the HIVE.”
The HIVE platform has gained recognition for its portable, handheld device that enables gentle capture, RNA stabilization, and processing of fragile cell types without specialized instrumentation. By integrating Factorial’s in-cell library preparation technology, researchers can now extend these capabilities to comprehensive single-cell DNA analysis and multi-omic profiling.
“Extending the HIVE platform to instrument-free single-cell DNA sequencing will accelerate discoveries in somatic mosaicism, tumor evolution, and gene editing by enabling large-scale, single-cell genomic studies,” added Chris Love, Co-Founder of Honeycomb Biotechnologies and Professor of Chemical Engineering at the Koch Institute at MIT.
The collaboration reflects both companies’ visions of removing technical constraints that limit scientific inquiry and broadens the aperture for genomic content available at single-cell resolution.
About Factorial Biotechnologies
Factorial Biotechnologies is an emerging single-cell sequencing company developing innovative in-cell library preparation technology. Founded in 2019, Factorial brings extensive expertise in next-generation sequencing, molecular biology, and bioinformatics. Factorial’s in-cell library prep solution enables single-cell NGS libraries to be prepared at workflow and content parity with bulk NGS libraries, unlocking new discoveries and actionable insights. The company’s Mosaic platform offers researchers accessible, high-throughput workflows with remarkable simplicity. Factorial is based in San Carlos, California. For more information, visit www.factorial.bio.
About Honeycomb Biotechnologies
Honeycomb Biotechnologies is focused on making scalable solutions for storage and single-cell genomic analysis of precious clinical samples. The company’s flagship HIVE platform is a single-use disposable device used for capturing, storing, and analyzing biological samples with single-cell resolution without requiring specialized instrumentation. Honeycomb enables translation of biological information from clinical specimens into high-resolution digital data that can be queried and analyzed with sequencing. Founded in 2017 and headquartered in Waltham, Massachusetts, Honeycomb is driving advances that enable single-cell RNA sequencing experiments to leverage cell preservation so samples can be collected from multiple sites and sequenced in integrated workflows. For more information, visit www.honeycomb.bio.
Media Contact:
Factorial Biotechnologies
John Wells
Founder & CEO
Jwells@factorial.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/factorial-biotechnologies-and-honeycomb-biotechnologies-partner-to-deliver-high-throughput-instrument-free-single-cell-dna-sequencing-302655593.html
SOURCE Factorial Biotechnologies
You May Also Like
Will Huge $8.3B Bitcoin Options Expiry Trigger Another Dump?
Why Staffing Agencies Need Hot Desk Booking Software to Scale Smarter
